Turning Point Benefit Group, Inc. Travere Therapeutics, Inc. Transaction History
Turning Point Benefit Group, Inc.
- $166 Billion
- Q3 2025
A detailed history of Turning Point Benefit Group, Inc. transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Turning Point Benefit Group, Inc. holds 19 shares of TVTX stock, worth $655. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19Holding current value
$655% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding TVTX
# of Institutions
270Shares Held
101MCall Options Held
2.36MPut Options Held
955K-
Janus Henderson Group PLC London, X010.6MShares$366 Million0.12% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$264 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY6.72MShares$232 Million2.47% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.61MShares$228 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C34.98MShares$172 Million0.14% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $2.21B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...